Avience Biomedicals IPO

About Avience Biomedicals Company

Avience Biomedicals Limited, incorporated in June 2024 as an ISO-certified company in Noida, Uttar Pradesh, India, is a biotechnology-focused manufacturer specializing in molecular diagnostic solutions, though its operations stem from the Avience Biomedicals Pvt. Ltd. entity founded in 2019 that gained expertise in supplying dengue test kits, blood bank equipment, and clinical reagents. The company began its operations with diagnostic solutions including Viral Transport Media (VTM) and test kits for diseases such as COVID-19, HIV, HBsAg, malaria, and dengue, then expanded its portfolio from IVD rapid test kits to comprehensive medical devices encompassing serology products, biochemistry analyzers, and biochemistry reagents, demonstrating steady evolution across diverse diagnostic categories. Its core business focuses exclusively on the B2B and B2G markets, with primary product segments including molecular diagnostics, in-vitro diagnostic (IVD) rapid test kits like Avisure Dengue IgG/IgM Ab & NS1 Ag Combo and Malaria PF/PV Antigen kits, serology products, and biochemistry analyzers serving pathology labs, microbiology labs, hospitals, and research centers nationwide and overseas. Key areas of expertise lie in molecular biotechnology, markers, genomics, and the IVD industry, supported by over 20 years of collective experience in these fields, with unique strengths including developing cutting-edge global innovations offering affordable options for rural and underprivileged populations while maintaining cost-effective solutions. Avience serves healthcare institutions across India and internationally through an operational philosophy prioritizing affordability, innovation, accessible healthcare for all, and acting as both manufacturer and distributor/trader of medical equipment to address industry challenges like diagnostic accessibility and cost barriers.